Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice

ACS Chemical Neuroscience

Volumn 1, Issue 5, 2010, Pages 366-380

  Jeng, Winnie ^a   Wells, Peter G ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b SANOFI   (France)

Author keywords

3,4 Methylenedioxymethamphetamine; Ecstasy; Neurodegeneration; Oxidative DNA damage; Prostaglandin H synthase; Reactive oxygen species

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; FREE RADICAL; ICOSATETRAYNOIC ACID; PROSTAGLANDIN H; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; GENDER; GENE DOSAGE; KNOCKOUT MOUSE; MOTOR COORDINATION; MOUSE; NERVE DEGENERATION; NONHUMAN; OXIDATION; PRIORITY JOURNAL; STEREOCHEMISTRY;

3,4-METHYLENEDIOXYMETHAMPHETAMINE; ECSTASY; NEURODEGENERATION; OXIDATIVE DNA DAMAGE; PROSTAGLANDIN H SYNTHASE; REACTIVE OXYGEN SPECIES;

ANIMALS; BEHAVIOR, ANIMAL; BLOTTING, WESTERN; BRAIN CHEMISTRY; CYCLOOXYGENASE 1; DEOXYGUANOSINE; DNA DAMAGE; DOPAMINERGIC NEURONS; FEMALE; FREE RADICALS; GENOTYPE; HALLUCINOGENS; MALE; MICE; MICE, KNOCKOUT; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; N-METHYLASPARTATE; NERVE DEGENERATION; OXIDATIVE STRESS; PRESYNAPTIC TERMINALS; PSYCHOMOTOR PERFORMANCE; REACTIVE OXYGEN SPECIES; STEREOISOMERISM;

MUS;

EID: 77953305867     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn900022w     Document Type: Article

References (66)

1. Nichols, D. E. (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens J. Psychoactive Drugs 18, 305-313
2. Broening, H. W., Bowyer, J. F., and Slikker, W. (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response J. Pharmacol. Exp. Ther. 275, 325-333
3. Kalant, H. (2001) The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs CMAJ 165, 917-928
4. Bolla, K. I., McCann, U. D., and Ricaurte, G. A. (1998) Memory impairment in abstinent MDMA ("Ecstasy") users Neurology 51, 1532-1537
5. McGuire, P. (2000) Long term psychiatric and cognitive effects of MDMA use Toxicol. Lett. 112-113, 153-156
6. Zakzanis, K. K. and Young, D. A. (2001) Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation Neurology 56, 966-969
7. Cadet, J. L. and Brannock, C. (1998) Free radicals and the pathobiology of brain dopamine systems Neurochem. Int. 32, 117-131
8. McCann, U. D., Szabo, Z., Scheffel, U., Dannals, R. F., and Ricaurte, G. A. (1998) Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings Lancet 352, 1433-1437
9. Obrocki, J., Buchert, R., Vaterlein, O., Thomasius, R., Beyer, W., and Schiemann, T. (1999) Ecstasy - long-term effects on the human central nervous system revealed by positron emission tomography Br. J. Psychiatry 175, 186-188
10. Hatzidimitriou, G., McCann, U. D., and Ricaurte, G. A. (1999) Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery J. Neurosci. 19, 5096-5107
11. Ali, S. F., Newport, G. D., Scallet, A. C. Z. B., Ferguson, S. A., Bailey, J. R., Paule, M. G., and Slikker, W. (1993) Oral administration of 3,4-methylenedioxymethamphetamine (MDMA) produces selective serotonergic depletion in the nonhuman primate Neurotoxicol. Teratol. 15, 91-96
12. Slikker, W., Ali, S. F., Scallet, A. C., Frith, C. H., Newport, G. D., and Bailey, J. R. (1988) Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA) Toxicol. Appl. Pharmacol. 94, 448-457
13. Green, A. R., Mechan, A. O., Elliott, J. M., O'Shea, E., and Colado, M. I. (2003) The pharmacology and clinical pharmacology of 3,4- methylenedioxymethamphetamine (MDMA, "ecstasy") Pharmacol. Rev. 55, 463-508
14. Colado, M. I., O'Shea, E., Esteban, B., Granados, R., and Green, A. R. (1999) In vivo evidence against clomethiazole being neuroprotective against MDMA ('ecstasy')-induced degeneration of rat brain 5-HT nerve terminals by a free radical scavenging mechanism Neuropharmacology 38, 307-314
15. Tucker, G. T., Lennard, M. S., Ellis, S. W., Woods, H. F., Cho, A. K., Lin, L. Y., Hiratsuka, A., Schmitz, D. A., and Chu, T. Y. (1994) The demethylenation of methylenedioxymethamphetamine ("ecstasy") by debrisoquine hydroxylase (CYP2D6) Biochem. Pharmacol. 47, 1151-1156
16. Monks, T. J., Jones, D. C., Bai, F., and Lau, S. S. (2004) The role of metabolism in 3,4-(±)-Methylenedioxyamphetamine and 3,4-(±)- methylenedioxymethamphetamine (Ecstasy) toxicity Ther. Drug Monit. 26, 132-136
17. de la Torre, R., Farre, M., Roset, P. N., Pizarro, N., Abanades, S., Segura, M., Segura, J., and Cami, J. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism and disposition Ther. Drug Monit. 26, 137-144
18. Warner, M., Hellmold, H., Yoshida, S., Liao, D., Hedlund, E., and Gustafsson, J. A. (1997) Cytochrome P450 in the breast and brain: role in tissue-specific activation of xenobiotics Mutat. Res. 376, 79-85
19. Sasame, H. A., Ames, M. M., and Nelson, S. D. (1977) Cytochrome P-450 and NADPH cytochrome c reductase in rat brain: formation of catechols and reactive catechol metabolites Biochem. Biophys. Res. Commun. 78, 919-926
20. Brady, J. F., Di Stefano, E. W., and Cho, A. K. (1986) Spectral and inhibitory interactions of (±)-3,4-methylenedioxyamphetamine (MDA) and (±)-3,4-methylenedioxymethamphetamine (MDMA) with rat hepatic microsomes Life Sci. 39, 1457-1464
21. Pelkonen, O., Maenpaa, J., Taavitsainen, P., Rautio, A., and Raunio, H. (1998) Inhibition and induction of human cytochrome P450 (CYP) enzymes Xenobiotica 28, 1203-1253 (Pubitemid 29017141)
22. Warner, M. and Gustafsson, J. A. (1994) Effect of ethanol on cytochrome P450 in the rat brain Proc. Natl. Acad. Sci. U.S.A. 91, 1019-1023
23. Colado, M. I., Williams, J. L., and Green, A. R. (1995) The hyperthermic and neurotoxic effects of 'Ecstasy' (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype Br. J. Pharmacol. 115, 1281-1289
24. Parman, T. and Wells, P. G. (2002) Embryonic prostaglandin H synthase-2 (PHS-2) expression and benzo[a]pyrene teratogenicity in PHS-2 knockout mice FASEB J. 16, 1001-1009
25. Parman, T., Wiley, M. J., and Wells, P. G. (1999) Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity Nat. Med. 5, 582-585
26. Wells, P. G., Kim, P. M., Laposa, R. R., Nicol, C. J., Parman, T., and Winn, L. M. (1997) Oxidative damage in chemical teratogenesis Mutat. Res. 396, 65-78
27. Wells, P. G., McCallum, G. P., Chen, C. S., Henderson, J. T., Lee, C. J. J., Perstin, J., Preston, T. J., Wiley, M. J., and Wong, A. W. (2009) Oxidative stress in developmental origins of disease: teratogenesis, neurodevelopmental deficits and cancer Toxicol. Sci. 108, 4-18
28. Wells, P., Kim, P., Nicol, C., Parman, T., and Winn, L. (1997) Reactive Intermediates, in Drug Toxicity in Embryonic Development (Kavlock, R. and Daston, D., Eds.) pp 453 - 518, Springer-Verlag, Heidelberg, Germany.
29. Parman, T., Chen, G., and Wells, P. G. (1998) Free radical intermediates of phenytoin and related teratogens. Prostaglandin H synthase-catalyzed bioactivation, electron paramagnetic resonance spectrometry, and photochemical product analysis J. Biol. Chem. 273, 25079-25088
30. Jeng, W., Ramkissoon, A., Parman, T., and Wells, P. G. (2006) Prostaglandin H synthase-catalyzed bioactivation of amphetamines to free radical intermediates that cause CNS regional DNA oxidation and nerve terminal neurodegeneration FASEB J. 20, 638-650
31. Eling, T. E., Thompson, D. C., Foureman, G. L., Curtis, J. F., and Hughes, M. F. (1990) Prostaglandin H synthase and xenobiotic oxidation Annu. Rev. Pharmacol. Toxicol. 30, 1-45
32. Wong, A. W., McCallum, G. P., Jeng, W., and Wells, P. G. (2008) Oxoguanine glycosylase 1 (OGG1) protects against methamphetamine-enhanced fetal brain oxidative DNA damage and neurodevelopmental deficits J. Neurosci. 28, 9047-9054
33. O'Callaghan, J. P. and Miller, D. B. (1994) Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse J. Pharmacol. Exp. Ther. 270, 741-751
34. Winn, L. M. and Wells, P. G. (1995) Phenytoin-initiated DNA oxidation in murine embryo culture, and embryo protection by the antioxidative enzymes superoxide dismutase and catalase: evidence for reactive oxygen species-mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity Mol. Pharmacol. 48, 112-120
35. Baumann, M. H., Wang, X., and Rothman, R. B. (2007) 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings Psychopharmacology 189, 407-424
36. Johnson, M. P., Hoffman, A. J., and Nichols, D. E. (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from supeffused rat brain slices Eur. J. Pharmacol. 132, 269-276
37. Goncalves, L. L., Ramkissoon, A., and Wells, P. G. (2009) Prostaglandin H synthase-1-catalyzed bioactivation of neurotransmitters, their precursors and metabolites: oxidative DNA damage and electron spin resonance spectroscopy studies Chem. Res. Toxicol. 22, 842-852
38. Schmidt, C. J., Levin, J. A., and Lovenberg, W. (1987) In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain Biochem. Pharmacol. 36, 747-755
39. Langenbach, R., Loftin, C., Lee, C., and Tiano, H. (1999) Cyclooxygenase knockout mice: models for elucidating isoform-specific functions Biochem. Pharmacol. 58, 1237-1246
40. Langenbach, R., Morham, S. G., Tiano, H. F., Loftin, C. D., Ghanayem, B. I., Chulada, P. C., Mahler, J. F., Lee, C. A., Goulding, E. H., and Kluckman, K. D. 1995, Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-induced inflammation and indomethacin-induced gastric ulceration Cell 83, 483-492
41. Dinchuk, J. E., Car, B. D., Focht, R. J., Johnston, J. J., Jaffee, B. D., Covington, M. B., Contel, N. R., Eng, V. M., Collins, R. J., and Czerniak, P. M. 1995, Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II Nature 378, 406-409
42. Morham, S. G., Langenbach, R., Loftin, C. D., Tiano, H. F., Vouloumanos, N., Jennette, J. C., Mahler, J. F., Kluckman, K. D., Ledford, A., and Lee, C. A. 1995, Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse Cell 83, 473-482
43. Kita, T., Shimada, K., Mastunari, Y., Wagner, G. C., Kubo, K., and Nakashima, T. (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice Neuropharmacology 39, 399-406 (Pubitemid 30052929)
44. Marnett, L. J. and DuBois, R. N. (2002) COX-2: a target for colon cancer prevention Annu. Rev. Pharmacol. Toxicol. 42, 55-80
45. Oka, A. and Takashima, S. (1997) Induction of cyclo-oxygenase 2 in brains of patients with Down's syndrome and dementia of Alzheimer type: specific localization in affected neurones and axons NeuroReport 8, 1161-1164
46. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., and Seitelberger, F. (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations J. Neurol. Sci. 20, 415-455
47. Compton, J., van Amelsvoort, T., and Murphy, D. (2002) Mood, cognition and Alzheimer's disease Best Pract. Res. Clin. Obstet. Gynaecol. 16, 357-370
48. Twelves, D., Perkins, K. S., and Counsell, C. (2003) Systematic review of incidence studies of Parkinson's disease Mov. Disord. 18, 19-31
49. Cadet, J. L., Ladenheim, B., Baum, I., Carlson, E., and Epstein, C. (1994) CuZn-superoxide dismutase (CuZnSOD) transgenic mice show resistance to the lethal effects of methylenedioxyamphetamine (MDA) and of methylenedioxymethamphetamine (MDMA) Brain Res. 655, 259-262
50. Fukumura, M., Cappon, G. D., Broening, H. W., and Vorhees, C. V. (1998) Methamphetamine-induced dopamine and serotonin reductions in neostriatum are not gender specific in rats with comparable hyperthermic responses Neurotoxicol. Teratol. 20, 441-448
51. Liechti, M. E., Gamma, A., and Vollenweider, F. X. (2001) Gender differences in the subjective effects of MDMA Psychopharmacology (Berlin) 154, 161-168
52. Dluzen, D. E. and McDermott, J. L. (2002) Estrogen, anti-estrogen, and gender: differences in methamphetamine neurotoxicity Ann. N.Y. Acad. Sci. 965, 136-156
53. Colado, M. I., Camarero, J., Mechan, A. O., Sanchez, V., Esteban, B., Elliott, J. M., and Green, A. R. (2001) A study of the mechanisms involved in the neurotoxic action of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') on dopamine neurones in mouse brain Br. J. Pharmacol. 134, 1711-1723
54. Darvesh, A. S. and Gudelsky, G. A. (2004) The relationship between hyperthermia and glycogenolysis in 3,4-methylenedioxymethamphetamine-induced serotonin depletion in rats Neurotoxicol. Teratol. 26, 571-577
55. O'Shea, E., Esteban, B., Camarero, J., Green, A. R., and Colado, M. I. (2001) Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain Neuropharmacology 40, 65-74
56. Yeh, S. Y. (1999) N-tert-butyl-alpha-Phenylnitrone protects against 3,4-methylenedioxymethamphetamine-induced depletion of serotonin in rats Synapse 31, 169-177
57. Spencer, A. G., Woods, J. W., Arakawa, T., Singer, I. I., and Smith, W. L. (1998) Subcellular localization of prostaglandin endoperoxide H synthases-1 and -2 by immunoelectron microscopy J. Biol. Chem. 273, 9886-9893
58. Mecocci, P., MacGarvey, U., Kaufman, A. E., Koontz, D., Shoffner, J. M., Wallace, D. C., and Beal, M. F. (1993) Oxidative damage to mitochondrial DNA shows marked age-dependent increases in human brain Ann. Neurol. 34, 609-616
59. Mecocci, P., MacGarvey, U., and Beal, M. F. (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease Ann. Neurol. 36, 747-751
60. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Franceschi, D., Sedler, M., Gatley, S. J., Miller, E., Hitzemann, R., Ding, Y. S., and Logan, J. (2001) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence J. Neurosci. 21, 9414-9418
61. Volkow, N. D., Chang, L., Wang, G. J., Fowler, J. S., Leonido-Yee, M., Franceschi, D., Sedler, M. J., Gatley, S. J., Hitzemann, R., Ding, Y. S., Logan, J., Wong, C., and Miller, E. N. (2001) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers Am. J. Psychiatry 158, 377-382
62. Zakzanis, K. K. and Campbell, Z. (2006) Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up Neurology 66, 740-741
63. Gavett, S. H., Madison, S. L., Chulada, P. C., Scarborough, P. E., Qu, W., Boyle, J. E., Tiano, H. F., Lee, C. A., Langenbach, R., Roggli, V. L., and Zeldin, D. C. (1999) Allergic lung responses are increased in prostaglandin H synthase-deficient mice J. Clin. Invest. 104, 721-732
64. Liu, L. and Wells, P. G. (1995) DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2'-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues Free Radical Biol. Med. 19, 639-648
65. Winn, L. M. and Wells, P. G. (1997) Evidence for embryonic prostaglandin H synthase-catalyzed bioactivation and reactive oxygen species-mediated oxidation of cellular macromolecules in phenytoin and benzo[a]pyrene teratogenesis Free Radical Biol. Med. 22, 607-621
66. Markwell, M. A., Haas, S. M., Tolbert, N. E., and Bieber, L. L. (1981) Protein Determination in Membrane and Lipoprotein Samples: Manual and Automated Procedures, in Methods in Enzymology (Colonick, S. P. and Kapla, N. O., Eds.) pp 296 - 303, Academic Press, Inc., New York.